https://www.selleckchem.com/pr....oducts/filanesib.htm
Patients with congenital adrenal hyperplasia (CAH) are exposed to hyperandrogenism and supraphysiologic glucocorticoids, both can increase risk of metabolic morbidity. Our aim was to evaluate cardiovascular and metabolic morbidity risk in a longitudinal study of patients with CAH spanning both childhood and adulthood. Patients with classic CAH followed for a minimum of 5 years during both childhood and adulthood (n=57) at the National Institutes of Health were included and compared with the U.S. general population using NHANES data. O
Like
Comment
Share
